Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Pathophysiologic foundation and clinical findings

N. S. Kleiman, A. M. Lincoff, E. M. Ohman, R. A. Harrington

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

The pathophysiologic basis for potent platelet inhibition in the acute coronary syndromes has been established. In the setting of PTCA for unstable angina and non-Q-wave myocardial infarction, there are clear data for a benefit of GP IIb/IIIa inhibition, whereas for primary PTCA in evolving myocardial infarction, preliminary data are very encouraging and a large- scale clinical trial is nearly completed. Glycoprotein IIb/IIIa inhibition as an adjunct to medical therapy for unstable angina is also the subject of encouraging preliminary data, and 3 large-scale clinical trials have just been completed. Preliminary data have also been accrued for GP IIb/IIIa inhibition as conjunctive therapy with thrombolytic agents, and large clinical trials are now commencing.

Original languageEnglish (US)
Pages (from-to)S32-S42
JournalAmerican Heart Journal
Volume136
Issue number4 II SUPPL.
DOIs
StatePublished - 1998

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Pathophysiologic foundation and clinical findings'. Together they form a unique fingerprint.

Cite this